Vitrolife Q1: A soft quarter - Redeye

The recorded sales growth is 0% in local currency due to an extended headwind for the Genetics business even if this was better than expected, and a softer quarter for Americas and EMEA. The OPEX level is contained, and we expect an adverse share price reaction and a negative consensus revision due to Vitrolife’s Q1.

Länk till analysen i sin helhet: https://www.redeye.se/research/996066/vitrolife-q1-a-soft-quarter?utm_source=finwire&utm_medium=RSS